Published in PLoS One on April 13, 2017
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain (1952) 6.71
Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol (1978) 4.47
Role of C5a in inflammatory responses. Annu Rev Immunol (2005) 4.38
A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 3.65
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52
Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A (2008) 2.74
Macrophage receptors for Mycobacterium tuberculosis. Infect Immun (1998) 2.42
Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol (2007) 2.25
Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (1982) 1.93
Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol (2001) 1.91
A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci U S A (1995) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol (1991) 1.70
Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci (2004) 1.66
Transthyretin mutations in health and disease. Hum Mutat (1995) 1.58
Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol (1998) 1.56
The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem (2005) 1.45
Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol (2008) 1.44
Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity (1997) 1.44
Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol (1999) 1.41
Does properdin crosslink the cellular and the humoral immune response? Immunol Today (1999) 1.39
Polyneuritic amyloidosis in a Japanese family. Arch Neurol (1968) 1.34
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood (2012) 1.26
C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J Neurochem (2009) 1.25
Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl (1976) 1.25
Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. Blood (2015) 1.25
Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Trans Assoc Am Physicians (1983) 1.24
Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res (1997) 1.24
Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun (1997) 1.20
Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid (2008) 1.19
In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest (1982) 1.15
Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol (1997) 1.07
Continual low-level activation of the classical complement pathway. J Exp Med (2001) 1.06
Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem (2007) 1.06
C1q and phagocytosis: the perfect complement to a good meal. J Leukoc Biol (2012) 1.05
The C5a receptor of neutrophils and macrophages. Agents Actions Suppl (1983) 1.05
Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol (2001) 1.03
Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation (2011) 1.02
Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol (1999) 1.01
C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytosis by human mononuclear phagocytes. Eur J Immunol (1988) 1.00
Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement (1985) 1.00
Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents. Mol Immunol (1992) 1.00
Complement component C1q regulates macrophage expression of Mer tyrosine kinase to promote clearance of apoptotic cells. J Immunol (2012) 0.98
C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med (2005) 0.95
Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo. Ann Thorac Surg (1997) 0.89
Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci (2009) 0.89
Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Mol Med (2007) 0.87
Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid (2009) 0.85
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine (2016) 0.83
Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res (2003) 0.83
Complement activation in acquired and hereditary amyloid neuropathy. J Peripher Nerv Syst (2000) 0.82
The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes. Immunology (2004) 0.80
Regulation of the alternative pathway of human complement by C1q. Mol Immunol (1987) 0.76